Trevi Therapeutics Quarterly Income Statement
NASDAQ: TRVIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
13.19+0.365 (+2.85%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Trevi Therapeutics revenue and earnings
Trevi Therapeutics reported a net loss of $17.8 million, compared with a loss of $12.3 million a year earlier. Diluted earnings per share came in at -$0.11.
Summary generated from market data by MetaCap's automated system. Methodology
Trevi Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 20.51M | 14.91M | 10.22M | 13.92M | 13.72M | 11.47M | 12.24M | 14.09M | 13.29M | 11.91M | 8.93M | 9.04M |
| Research & Development | 15.15M | 9.94M | 6.19M | 10.09M | 9.39M | 7.81M | 9.33M | 11.22M | 10.02M | 8.80M | 6.52M | 6.32M |
| Operating Income | -20.51M | -14.91M | -10.22M | -13.92M | -13.72M | -11.47M | -12.24M | -14.09M | -13.29M | -11.91M | -8.93M | -9.04M |
| Interest Expense | — | — | 0 | 0 | 0 | — | 1.00K | 1.00K | 1.00K | 1.00K | 4.00K | 3.00K |
| Other Income (Expense) | 2.69M | 1.70M | 1.89M | 2.10M | 1.40M | 1.12M | 844.00K | 814.00K | 929.00K | 996.00K | 1.13M | 1.33M |
| Pretax Income | -17.82M | -13.21M | -8.33M | -11.82M | -12.32M | -10.35M | -11.40M | -13.27M | -12.36M | -10.91M | -7.80M | -7.71M |
| Income Tax | -19.00K | -20.00K | -16.00K | -15.00K | -21.00K | -11.00K | 16.00K | -31.00K | -8.00K | -8.00K | 18.00K | -13.00K |
| Net Income | -17.80M | -13.19M | -8.32M | -11.80M | -12.30M | -10.34M | -11.41M | -13.24M | -12.35M | -10.90M | -7.82M | -7.70M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.11 | -0.09 | -0.06 | -0.08 | -0.09 | -0.09 | -0.11 | -0.13 | -0.12 | -0.11 | -0.08 | -0.08 |
| EPS (Diluted) | -0.11 | -0.09 | -0.06 | -0.08 | -0.09 | -0.09 | -0.11 | -0.13 | -0.12 | -0.11 | -0.08 | -0.08 |
| Shares Outstanding (Basic) | 156.60M | 145.59M | — | 145.10M | 130.35M | 117.61M | — | 101.28M | 101.04M | 99.52M | — | 99.33M |
| Shares Outstanding (Diluted) | 156.60M | 145.59M | — | 145.10M | 130.35M | 117.61M | — | 101.28M | 101.04M | 99.52M | — | 99.33M |
| EBITDA | -20.48M | -14.88M | -10.19M | -13.88M | -13.68M | -11.43M | -12.21M | -14.05M | -13.25M | -11.87M | -8.90M | -9.01M |
This table shows 12 quarterly periods of Trevi Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 13 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow TRVI's reporting calendar. What is a income statement?